Research progress of effective components of Astragalus on prevention and treatment of organ fibrosis
10.16438/j.0513-4870.2023-0313
- VernacularTitle:黄芪有效成分防治器官纤维化的研究进展
- Author:
Shi-fen LI
;
Ruo-xuan YANG
;
Jian SUN
;
Hai-hai LIANG
- Publication Type:Research Article
- Keywords:
astragalus;
astragalus polysaccharide;
astragalus membranaceus saponin;
astragalus flavonoid;
organ fibrosis;
extracellular matrix
- From:
Acta Pharmaceutica Sinica
2023;58(8):2168-2179
- CountryChina
- Language:Chinese
-
Abstract:
Astragalus, which was first documented in Shennong Bencao Jing, is the dried root of Astragalus membranaceus (Fisch.) Bge. or Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao. The active ingredients astragalus membranaceus saponins (AMS), astragalus polysaccharides (APS) and astragalus flavonoids (AFS) have pharmacological effects such as anti-tumor properties, lowering blood sugar, regulating lipid metabolism, cardiovascular protection, anti-oxidation, bone protection, anti-fibrosis, etc. Fibrosis affects almost all organs, particularly vital organs such as the lungs, liver, heart and kidneys. The primary pathological changes of fibrosis involve abnormal increase of myofibroblasts and excessive deposition of extracellular matrix (ECM) components, which lead to the formation of scar tissue, ultimately resulting in fibrosis and even functional loss or failure of organs, which seriously threatens human health and life. Recent, studies have shown that Astragalus membranaceus has a good therapetuic effect on organ fibrosis. This article reviews the current advances of Astragalus in the prevention and treatment of fibrosis of lungs, liver, heart, kidneys and other important organs.
